Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Abstract: The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices including protein matrix suture material and meshes, skin/bone/tissue grafts, biocompatible electricity conducting matrices, clear protein matrices, protein matrix adhesion prevention barriers, cell scaffolding and other biocompatible protein matrix devices. Furthermore, the present invention relates to protein matrix materials and devices made by forming a film comprising one or more biodegradable protein materials, one or more biocompatible solvents and optionally one or more pharmacologically active agents.

Abstract: The present invention relates to supramolecular polymers containing sequence-selective hydrogen bonding subunits in their backbone which form double helices. The invention allows for tuning of the numbers and sequences of donor/acceptor units incorporated in any one crosslinking hydrogen bonding subunit and hence tuning of the interaction strength not only through the amount of crosslinking material incorporated but also through modulation of the strength of the crosslinking interactions. It also allows for the incorporation of more than one type of crosslinking agent in the material allowing for multiple strengths of crosslinking which are each tunable with regard to disruption from solvent, temperature and stress. Hydrogen bond strength between oligomeric chains can be tailored through modification of the numbers and sequences of the donors/acceptors in the oligomers.

Abstract: The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices including protein matrix suture material and meshes, skin/bone/tissue grafts, biocompatible electricity conducting matrices, clear protein matrices, protein matrix adhesion prevention barriers, cell scaffolding and other biocompatible protein matrix devices. Furthermore, the present invention relates to protein matrix materials and devices made by forming a film comprising one or more biodegradable protein materials, one or more biocompatible solvents and optionally one or more pharmacologically active agents.

Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Abstract: An agricultural item comprising a biodegradable polyhydroxyalkanoate copolymer comprising two randomly repeating monomer units. The first randomly repeating monomer unit has the structure: wherein R1 is H or a C1-2 alkyl, and n is 1 or 2; and the second randomly repeating monomer unit has the structure: wherein R2 is a C3-19 alkyl or a C3-19 alkenyl. At least 50% of the randomly repeating monomer units have the structure of the first randomly repeating monomer unit.

Abstract: In an agricultural chemicals composition which is scattered by being thrown directly into a submerged paddy field, it is an object to provide a composition having an excellent spreadability without stagnation of an agrochemically active ingredient at the point of treatment (application), and in particular to provide a labor-saving formulation for scattering (application) which contains a liquid agrochemically active ingredient at room temperature, and to provide an agricultural chemicals composition containing a liquid agrochemically active ingredient at room temperature in high concentrations, which have been difficult to be realized.

Abstract: Skin-growth-enhancing compounds and compositions including a therapeutically effective amount of at least one electron active compound, or a pharmaceutically acceptable derivative thereof, that has at least two polyvalent cations, at least one of which has a first valence state and at least one of which has a second, different valence state. Preferred compounds include Bi(III,V) oxide, Co(II,III) oxide, Cu(I,III) oxide, Fe(II,III) oxide, Mn(II,III) oxide, and Pr(III,IV) oxide, and Ag(I,III) oxide, or a combination thereof. These compounds may be in a crystalline state having metallic cations of two different valences, or electronic states, in the inorganic crystal. Also included are articles containing such compositions, such as wound dressings, and methods for facilitating or enhancing skin growth using these compounds, compositions, and articles, such as for the treatment or management of burns or skin grafts.

Abstract: A stable, solid product of selected starches, active agricultural agents and optionally surfactants and or adjuvants which is readily dispersible in aqueous medium and compatible when dispersed.

Abstract: The present invention provides a composition for attracting scarabs. Liquid and solid formulations are provided, along with methods for their use, for controlling or eliminating scarabs, and/or protecting plants susceptible to scarab damage.

Abstract: Dry, stable, high available halogen sanitizing granular compositions with a rapid rate of dissolution comprising halogenated 1,3,5-triazine-2,4,6-triones and a dissolution accelerant that is an alkali metal salt of 1,3,5-triazine-2,4,6-trione are disclosed. The disclosed compositions may include inorganic and/or organic disintegration agents. Additionally, these compositions may contain other performance enhancing additives such as water clarifiers, algaestats/algaecides, surfactants, glidants, processing aids, and binders. These UV stable sanitizing compositions contain a high available halogen content, and are stable even when stored in high-humidity environments.

Abstract: A method and compositions for reducing post-surgical adhesion formation/reformation in mammals following surgical injury to a body cavity or organs situated therein. The aqueous compositions comprising pentoxifylline and a polyoxyalkylene block copolymer are applied to the injured areas subsequent to surgical injury.

Abstract: The present invention describes the use of a combination of an agrochemically active compound and a solid carrier material which surrounds the active compound, to suppress antagonistic interactions in a mixture comprising the active compound surrounded by the carrier material, and at least one further agrochemically active compound. Preferred formulations comprising such a combination include herbicides combined with a carrier material together with a safener and/or a growth regulator. Using the formulations according to the present invention, it is possible to suppress antagonistic interactions between different active compounds.

Abstract: Pharmaceutical compositions comprising a macromolecular pharmaceutical agent in mixed micellar form are disclosed. The mixed micelles are formed from an alkali metal alkyl sulfate, and at least three different micelle-forming compounds as described in the specification. Micelle size ranges between about 1 and 10 nanometers. Methods for making and using the compositions are also disclosed. A preferred method for administering the present composition is through the buccal region of the mouth.

Abstract: A mixed liposome pharmaceutical composition with multilamellar vesicles is provided. The vesicles are comprised of a pharmaceutical agent, membrane-mimetic amphiphiles and various phospholipids. A method of making the composition using high speed mixing of the amphiphiles and phospholipids is also provided.

Abstract: There is provided a method of treating a human subject to prevent leakage of serum proteins from capillary endothelial junctions during a period of increased capillary permeability. The method comprises administering to a subject an effective amount of a composition containing hydroxyethyl starch, dextran or hydroxyethyl starch and dextran. The compositions contain these macromolecules in a molecular size and concentration to effectively seal the capillary junctions and stabilize the capillary membranes. The sealant effect is accomplished by a biophysical process due to the adhesiveness and configuration of the macromolecules, and because of their size. There is also provided a means of treating viral and other bacterial infections and cancer, by introducing into the composition of polysaccharide(s) a biological agent, preferably interleukin-2.

Abstract: A pharmaceutical composition in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin or an ascomycin, and a carrier medium.

Abstract: The invention relates to macrocyclic substances which are bioregulatory active and a method for their synthetic production as well as its isolation from various starting materials. The application of these active substances as such or in combination with other active substances for enzyme regulation and bioregulation is also described.

Abstract: Cosmetic/pharmaceutical/hygienic compositions (e.g., lipcolors) are formulated as homogeneous and stable, supple dough extrudates, said supple dough extrudates having at least one thermally-unmodified but normally heat-sensitive compound (for example a volatile compound and/or a compound having a low flash point) and at least one elevated melting temperature T compound (for example a wax) homogeneously distributed therethrough.

Abstract: Disclosed are modified bryostatins and their use as anticancer drugs.

Abstract: A method and compositions for reducing post-surgical adhesion formation/reformation in mammals following surgical injury to a body cavity or organs situated therein. The aqueous compositions comprising pentoxifylline and a polyoxyalkylene block copolymer are applied to the injured areas subsequent to surgical injury.

Abstract: Disclosed are pharmaceutical compositions containing solid dispersions in the form of co-precipitates, which solid dispersions contain rapamycin and a carrier medium, and methods of treatment utilizing such pharmaceutical compositions.

Abstract: Hydrodynamic baits for the control of orthopterous insects are disclosed which contain an attractant, a humectant and a gel former. The baits are designed to function in harsh and/or dynamic microclimates such as for example commercial kitchens or outdoor environments subject to typical circadian influences such as temperature and moisture. A further advantage of the disclosed baits is their lack of attractiveness to mammals.

Abstract: The invention provides an extracellular matrix for enhancing wound healing. The extracellular matrix comprises a recombinant fibronectin protein and a backbone matrix, wherein the recombinant fibronectin protein comprises peptides from two or more fibronectin domains. The extracellular matrix facilitates wound healing by providing hemostasis and, in addition, an environment that intrinsically recruits new tissue cells to the wound site. The extracellular matrix according to the subject invention is thus used in a method for enhancing wound healing. The method comprises applying the extracellular matrix to the wound.

Abstract: A stable non-aqueous carrier for personal care compositions comprising:a) about 80-98% by weight of a liquid polyoxyalkylene glycol of MW=3000-100000;b) about 2-20% by weight of a non-ionic solid triblock EO/PO/EO copolymer of MW=8500-25,000.

Abstract: A composition of matter comprising a hyaluronate functionalized with a hydrazide at glucuronic acid sites of said hyaluronate, wherein the hydrazide is chosen from a group consisting of: monohydrazide and hydrazides comprising three or more amine groups.

Abstract: Described is a method for repelling insects by use of oxymethyl cyclohexane derivatives of the structure ##STR1## wherein Z is methylene; n is 0 or 1; each of the wavy lines represents a carbon-carbon single bond or no bond; the dashed line represents a carbon-carbon double bond or a carbon-carbon single bond; each of R.sub.2, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are the same or different and each represents hydrogen or methyl; and R.sub.1 represents hydrogen, acetyl or ethoxycarbonyl with the provisos:(i) that n is 1 and each of the wavy lines represents a carbon-carbon single bond when R.sub.1, R.sub.2, and R.sub.6, are each hydrogen, R.sub.5, R.sub.7 and R.sub.8 are each methyl and the dashed line is a carbon-carbon single bond;(ii) n is 0 and each of the wavy lines represents no bond when R.sub.5 and R.sub.7 are each hydrogen and R.sub.6 and R.sub.8 are each methyl;(iii) R.sub.2 is methyl only when R.sub.1 is ethoxycarbonyl; and(iv) the dashed line is a carbon-carbon single bond only when R.sub.

Abstract: The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.

Abstract: This invention relates to a water soluble matrix composition comprising an anionic surfactant, a C.sub.6 to C.sub.18 alkyl pyrrolidone, urea and a water insoluble copolymer of vinyl pyrrolidone with not more than 50 wt. % of a comonomer selected from the group of an .alpha.-olefin, vinyl acetate, an acrylic or methacrylic acid ester and methacrylamide as a free flowing particulate solid which matrix is suitably mixed with a water insoluble, chemically active component, such as an agrochemical, to provide a clear sprayable film forming emulsion, such as a non-leachable film on a plant or other substrate surface. The invention also relates to the method of preparing the matrix and to the incorporation of an agrochemical concentrate and plant spray composition.

Abstract: A protein-polysaccharide complex is used as a non-toxic and sustained release carrier for insecticides, herbicides, foliar nutrients and mixtures thereof. Methods for using a solution, solid or flowable impregnated protein-polysaccharide complex as a delivery agent for the control of plant populations and insect populations and as a preservative for cut flowers are described.

Abstract: Novel O.sup.6 -substituted guanine compounds and pharmaceutical compositions thereof are useful for effectively reducing O.sup.6 -alkylguanine-DNA alkyltransferase (AGT). The novel compounds are useful for treating tumors and when used with anti-neoplastic alkylating agents enhance the chemotherapeutic treatment of tumor cells in a host.

Abstract: The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.

Abstract: The present invention is an injectable medical composition useful for replacing natural lubricating fluids in the body of humans or animals. The method and composition can be used for the treatment of joints and other parts of the body wherein natural lubrication between surfaces is deficient or where additional lubrication is required. The composition comprises a hydrophilic polymer suspended in a hydrophobic carrier so that the suspension is easily injectable into the desired body part. After injection, the carrier diffuses away from the polymer and is replaced by aqueous body fluids thereby causing the polymer to absorb or adsorb water forming a viscous, lubricating fluid.

Abstract: The present invention provides aqueous inclusion complexes of certain known benzothiophene compounds, particularly Raloxifene, and water soluble cyclodextrins. Also provided are pharmaceutical compositions of such inclusion complexes, and methods of using these complexes for inhibiting bone loss and reducing serum cholesterol in mammals.

Abstract: The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.

Abstract: Disclosed is a sustained release liquid aqueous ophthalmic delivery system and a method of providing a slow and sustained release of ophthalmic treating agents to the eye of a mammal which comprises administering to the eye of a said mammal an effective amount of a homogeneous liquid aqueous ophthalmic pharmaceutical composition, of pH between about 3.0 and about 6.2, which is adminstrable in drop form and which comprises an ophthalmically effective concentration of a said ophthalmic treating agent and about 0.05% to about 10% by weight of the polymer chitosan; said polymer consisting essentially of(A) monomeric .beta.(1.fwdarw.4)-D-glucosamine linked units and of(B) monomeric .beta.(1.fwdarw.

Abstract: Water-soluble cyclic imide thione activated polyalkylene oxides having improved hydrolytic stability are disclosed. Methods of forming and conjugating the activated polyalkylene oxides with biologically active nucleophiles are also disclosed.

Abstract: The systemic absorption after intranasal administration of certain drugs, in particular pharmacologically active polypeptides is enhanced in the presence of a phospholipid, such as a phosphatidylcholine (a lecithin), preferably admixed with a vegetable oil.

Abstract: The invention provides a method of targeting an x-ray contrast agent to a specific population of cells or organ. Targeting may be accomplished by forming a complex of a radiopaque label with a saccharide capable of interacting with a cell receptor. The resulting complex may then be internalized into the specific population of cells or organ by receptor mediated endocytosis. In one embodiment of the invention, the radiopaque label may include a compound containing iodine and the saccharide may include arabinogalactan, galactan, or derivatives thereof. The invention provides a method for determining the metabolic viability or disease state of the target cells or organ by visualizing the extent, mode of uptake and excretion of the targeted x-ray contrast agent by x-ray or computer tomography.

Abstract: The present invention provides compositions of matter and methods for treating a human subject to prevent leakage of serum albumin from capillary endothelial junctions during a period of increased capillary permeability. The method comprises administering to the human subject an effective capillary pore sealing amount of a macromolecule which is biodegradable, non-toxic, globular in shape, with a molecular weight range from about 100,000 daltons to about 1,000,000 daltons and a pharmaceutically acceptable carrier. The composition of matter comprises a fraction derived from hydroxyethyl starch.

Abstract: Etofenamate is used for the preparation of compositions useful in the treatment of bacterial, viral or fungicidal inflammations in the region of the oral cavity.

Abstract: Polymers are provided that are useful for making biodegradable sustained release agent dispensers and which contain at least one of the following mer units (I) and (II) ##STR1## wherein X is a quadrivalent organic grouping, A and B are hydrogen or lower alkyl, and R is hydrocarbyl or oxyhydrocarbyl of 1 to 14 carbon atoms and, if oxyhydrocarbyl, containing 1 to 4 oxy groups, and may be either aliphatic or aryl, unsubstituted or substituted with one or more lower alkyl, amino, nitro or halogen moieties. Methods of synthesizing the novel polymers are also provided, as biodegradable beneficial agent dispensers prepared using the novel polymers.

Abstract: The invention relates to a plant-protective solution containing 2.5 to 40 % by weight of one or more water-insoluble plant-protective ingredient(s) 20 to 71.5 % by weight of dimethylformamide and/or dimethylsulfoxide and/or acetone as water-miscible solvent, 10 to 71.5 % by weight of furfurol and/or furfuryl alcohol as partially water-miscible solvent, 1 to 15 % by weight of commonly used additives such as anionic and/or nonionic surface active agents and macromolecules.The invention also relates to the ready-for-use plant-protective suspension containing 0.2 to 10 % by weight of one or more water-insoluble plant-protective ingredient(s) with a particle size of 0.1 to 50 .mu.m, 0 to 60 % by weight of a fertilizer, 0.2 to 10 % by weight of dimethylformamide and/or dimethylsulfoxide and/or acetone as water-miscible solvent, 0.2 to 10 % by weight of furfurol and/or furfuryl alcohol as partially water-miscible solvent, 0.05 to 2.

Abstract: An organic solvent soluble active agent containing water-insoluble hydrophilic hydrogel comprising a copolymer of (A) a water-soluble monoolefinic monomer or a mixture thereof optimally containing up to 50% thereof of one or more water-insoluble mono-olefinic monomers and (B) a terminally diolefinic hydrophobic macromer containing polypropylene oxide or polytetramethylene oxide units prepared in the presence of an effective macromer expanding amount of a macromer soluble compound of the formulaR'--R"--O.sub.n R"'where R', R", R"' and n are as defined in the claims, hydrogels useful in the loading of such active agents, their preparation, and use are disclosed.

Abstract: Biodegradible polymers are provided which may contain a biologically active substance, e.g. a drug such as insulin, which is released over a period of time as the polymer erodes when in contact with a body fluid. The polymer contains an amine functionality whereby it erodes faster at low acid pH's than at higher acid pH's. As an example, the polymer may contain insulin and may contain or may have an encapsulating hydrogel containing glucose oxidase. As the blood sugar level of a diabetic person rises, e.g., after a meal, glucose diffuses into the polymer or hydrogel and is converted to gluconic acid which lowers the pH, and accelerates erosion and the release of insulin.

Abstract: The invention concerns a collagen sponge which has a denaturation temperature of at least 37.degree. C., is not cross-linked and in one of its two embodiments forms an optically clear solution in aqueous medium. As compared with the collagen sponges previously known, it is particularly suitable as support material for pharmaceutical and cosmetic active substances since it has a higher denaturation temperature than the latter and dissolves again in contact with body fluid. The collagen sponge of the invention is prepared from an optically clear collagen solution by precipitation with neutral salts, dissolving and reprecipitation and then subjecting the collagen to freeze-drying without removal of the precipitation salt. Acid-swollen collagens and/or cellulose or cellulose derivatives can also be added to the solution, whereby the physical properties of the collagen sponge can be affected.

Abstract: Biodegradible polymers are provided which may contain a biologically active substance, e.g. a drug such as insulin, which is released over a period of time as the polymer erodes when in contact with a body fluid. The polymer contains an amine functionality whereby it erodes faster at low acid pH's than at higher acid pH's. As an example, the polymer may contain insulin and may contain or may have an encapsulating hydrogel containing glucose oxidase. As the blood sugar level of a diabetic person rises, e.g., afte a meal, glucose diffuses into the polymer or hydrogel and is converted to gluconic acid which lowers the pH, and accelerates erosion and the release of insulin.